OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Small molecule Mcl-1 inhibitors for the treatment of cancer
Johannes Belmar, Stephen W. Fesik
Pharmacology & Therapeutics (2014) Vol. 145, pp. 76-84
Open Access | Times Cited: 161
Johannes Belmar, Stephen W. Fesik
Pharmacology & Therapeutics (2014) Vol. 145, pp. 76-84
Open Access | Times Cited: 161
Showing 1-25 of 161 citing articles:
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Adrian Ally, Miruna Balasundaram, Rebecca Carlsen, et al.
Cell (2017) Vol. 169, Iss. 7, pp. 1327-1341.e23
Open Access | Times Cited: 2104
Adrian Ally, Miruna Balasundaram, Rebecca Carlsen, et al.
Cell (2017) Vol. 169, Iss. 7, pp. 1327-1341.e23
Open Access | Times Cited: 2104
Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1894
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1894
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi, Wayne J. Fairbrother, Joel D. Leverson, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 4, pp. 273-284
Closed Access | Times Cited: 784
Avi Ashkenazi, Wayne J. Fairbrother, Joel D. Leverson, et al.
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 4, pp. 273-284
Closed Access | Times Cited: 784
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber
Cancer Discovery (2015) Vol. 5, Iss. 5, pp. 475-487
Open Access | Times Cited: 564
Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber
Cancer Discovery (2015) Vol. 5, Iss. 5, pp. 475-487
Open Access | Times Cited: 564
FBXW7: a critical tumor suppressor of human cancers
Chien‐Hung Yeh, Marcia Bellon, Christophe Nicot
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 440
Chien‐Hung Yeh, Marcia Bellon, Christophe Nicot
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 440
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy
Rongqing Pan, Vivian Ruvolo, Hong Mu, et al.
Cancer Cell (2017) Vol. 32, Iss. 6, pp. 748-760.e6
Open Access | Times Cited: 253
Rongqing Pan, Vivian Ruvolo, Hong Mu, et al.
Cancer Cell (2017) Vol. 32, Iss. 6, pp. 748-760.e6
Open Access | Times Cited: 253
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Ιωάννα Πέττα, Sam Lievens, Claude Libert, et al.
Molecular Therapy (2015) Vol. 24, Iss. 4, pp. 707-718
Open Access | Times Cited: 200
Ιωάννα Πέττα, Sam Lievens, Claude Libert, et al.
Molecular Therapy (2015) Vol. 24, Iss. 4, pp. 707-718
Open Access | Times Cited: 200
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Gizem Akçay, Matthew A. Belmonte, Brian Aquila, et al.
Nature Chemical Biology (2016) Vol. 12, Iss. 11, pp. 931-936
Closed Access | Times Cited: 179
Gizem Akçay, Matthew A. Belmonte, Brian Aquila, et al.
Nature Chemical Biology (2016) Vol. 12, Iss. 11, pp. 931-936
Closed Access | Times Cited: 179
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Mérino, James R. Whittle, François Vaillant, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 401
Closed Access | Times Cited: 176
Delphine Mérino, James R. Whittle, François Vaillant, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 401
Closed Access | Times Cited: 176
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Andrew H. Wei, Andrew W. Roberts, Andrew Spencer, et al.
Blood Reviews (2020) Vol. 44, pp. 100672-100672
Open Access | Times Cited: 176
Andrew H. Wei, Andrew W. Roberts, Andrew Spencer, et al.
Blood Reviews (2020) Vol. 44, pp. 100672-100672
Open Access | Times Cited: 176
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Simon J. Cook, Kate Stuart, Rebecca Gilley, et al.
FEBS Journal (2017) Vol. 284, Iss. 24, pp. 4177-4195
Open Access | Times Cited: 148
Simon J. Cook, Kate Stuart, Rebecca Gilley, et al.
FEBS Journal (2017) Vol. 284, Iss. 24, pp. 4177-4195
Open Access | Times Cited: 148
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Cristina Correia, Sun Hee Lee, X. Wei Meng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2015) Vol. 1853, Iss. 7, pp. 1658-1671
Open Access | Times Cited: 147
Cristina Correia, Sun Hee Lee, X. Wei Meng, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2015) Vol. 1853, Iss. 7, pp. 1658-1671
Open Access | Times Cited: 147
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Milan Bruncko, Le Wang, George S. Sheppard, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 5, pp. 2180-2194
Closed Access | Times Cited: 145
Milan Bruncko, Le Wang, George S. Sheppard, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 5, pp. 2180-2194
Closed Access | Times Cited: 145
Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia
Denis E. Reyna, Thomas P. Garner, Andrea López, et al.
Cancer Cell (2017) Vol. 32, Iss. 4, pp. 490-505.e10
Open Access | Times Cited: 145
Denis E. Reyna, Thomas P. Garner, Andrea López, et al.
Cancer Cell (2017) Vol. 32, Iss. 4, pp. 490-505.e10
Open Access | Times Cited: 145
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams, Sean Clark-Garvey, Pierluigi Porcu, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 136
Clare M. Adams, Sean Clark-Garvey, Pierluigi Porcu, et al.
Frontiers in Oncology (2019) Vol. 8
Open Access | Times Cited: 136
ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca2+ signaling
Mart Bittremieux, Jan B. Parys, Paolo Pinton, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2016) Vol. 1863, Iss. 6, pp. 1364-1378
Open Access | Times Cited: 133
Mart Bittremieux, Jan B. Parys, Paolo Pinton, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2016) Vol. 1863, Iss. 6, pp. 1364-1378
Open Access | Times Cited: 133
Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
Bibi Kulsoom, Tahir Shamsi, Nasir Ali Afsar, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 403-416
Open Access | Times Cited: 125
Bibi Kulsoom, Tahir Shamsi, Nasir Ali Afsar, et al.
Cancer Management and Research (2018) Vol. Volume 10, pp. 403-416
Open Access | Times Cited: 125
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Bin Chen, Lana X. Garmire, Diego F. Calvisi, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 4, pp. 238-251
Open Access | Times Cited: 118
Bin Chen, Lana X. Garmire, Diego F. Calvisi, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 4, pp. 238-251
Open Access | Times Cited: 118
Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?
Nelson G. M. Gomes, Florence Lefranc, Anake Kijjoa, et al.
Marine Drugs (2015) Vol. 13, Iss. 6, pp. 3950-3991
Open Access | Times Cited: 117
Nelson G. M. Gomes, Florence Lefranc, Anake Kijjoa, et al.
Marine Drugs (2015) Vol. 13, Iss. 6, pp. 3950-3991
Open Access | Times Cited: 117
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
Michelle M. Williams, Rebecca S. Cook
Oncotarget (2015) Vol. 6, Iss. 6, pp. 3519-3530
Open Access | Times Cited: 106
Michelle M. Williams, Rebecca S. Cook
Oncotarget (2015) Vol. 6, Iss. 6, pp. 3519-3530
Open Access | Times Cited: 106
New dimension in therapeutic targeting of BCL-2 family proteins
Samaher Besbes, Massoud Mirshahi, Marc Pocard, et al.
Oncotarget (2015) Vol. 6, Iss. 15, pp. 12862-12871
Open Access | Times Cited: 100
Samaher Besbes, Massoud Mirshahi, Marc Pocard, et al.
Oncotarget (2015) Vol. 6, Iss. 15, pp. 12862-12871
Open Access | Times Cited: 100
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
Yafang Pan, Yu Zhang, Wenwen Liu, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 2
Open Access | Times Cited: 89
Yafang Pan, Yu Zhang, Wenwen Liu, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 2
Open Access | Times Cited: 89
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Aditi Shastri, Gaurav S. Choudhary, Margarida Teixeira, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 12, pp. 5479-5488
Open Access | Times Cited: 86
Aditi Shastri, Gaurav S. Choudhary, Margarida Teixeira, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 12, pp. 5479-5488
Open Access | Times Cited: 86
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Fengzhi Li, Ieman Aljahdali, Renyuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 75
Fengzhi Li, Ieman Aljahdali, Renyuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 75
Development of Mcl-1 inhibitors for cancer therapy
Arvind Negi, Paul V. Murphy
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 113038-113038
Open Access | Times Cited: 73
Arvind Negi, Paul V. Murphy
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 113038-113038
Open Access | Times Cited: 73
